Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Inflammation Research
Erschienen in: Inflammation Research 8/2021

04.06.2021 | COVID-19 | Review Zur Zeit gratis

The role of 5-lipoxygenase in the pathophysiology of COVID-19 and its therapeutic implications

verfasst von: Nohora Cristina Ayola-Serrano, Namrata Roy, Zareena Fathah, Mohammed Moustapha Anwar, Bivek Singh, Nour Ammar, Ranjit Sah, Areej Elba, Rawan Sobhi Utt, Samuel Pecho-Silva, Alfonso J. Rodriguez-Morales, Kuldeep Dhama, Sadeq Quraishi

Erschienen in: Inflammation Research | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, known as coronavirus disease 2019 (COVID-19) causes cytokine release syndrome (CRS), leading to acute respiratory distress syndrome (ARDS), acute kidney and cardiac injury, liver dysfunction, and multiorgan failure. Although several studies have discussed the role of 5-lipoxygenase (5-LOX) in viral infections, such as influenzae and SARS, it remains unexplored in the pathophysiology of COVID-19. 5-LOX acts on free arachidonic acid (AA) to form proinflammatory leukotrienes (LTs). Of note, numerous cells involved with COVID-19 (e.g., inflammatory and smooth muscle cells, platelets, and vascular endothelium) widely express leukotriene receptors. Moreover, 5-LOX metabolites induce the release of cytokines (e.g., tumour necrosis factor-α [TNF-α], interleukin-1α [IL-1α], and interleukin-1β [IL-1β]) and express tissue factor on cell membranes and activate plasmin. Since macrophages, monocytes, neutrophils, and eosinophils can express lipoxygenases, activation of 5-LOX and the subsequent release of LTs may contribute to the severity of COVID-19. This review sheds light on the potential implications of 5-LOX in SARS-CoV-2-mediated infection and the anticipated therapeutic role of 5-LOX inhibitors.
Literatur
1.
Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, et al. Coronavirus disease 2019–COVID-19. Clin Microbiol Rev [Internet]. 2020;33:1–48.
2.
Yang Y, Peng F, Wang R, Yange M, Guan K, Jiang T, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun. 2020;109:102434.PubMedPubMedCentralCrossRef
3.
Biscayart C, Angeleri P, Lloveras S, Chaves TDSS, Schlagenhauf P, Rodríguez-Morales AJ. The next big threat to global health? 2019 novel coronavirus (2019-nCoV): What advice can we give to travellers? – Interim recommendations January 2020, from the Latin-American Society for Travel Medicine (SLAMVI). Travel Med Infect Dis. 2020;33:101567.PubMedPubMedCentralCrossRef
4.
5.
Millán-Oñate J, Rodriguez-Morales AJ, Camacho-Moreno G, Mendoza-Ramírez H, Rodríguez-Sabogal IA, Álvarez-Moreno C. A new emerging zoonotic virus of concern: the 2019 novel Coronavirus (COVID-19). Infection. 2020;24:187–92.CrossRef
6.
7.
8.
9.
Lin H-C, Lin T-H, Wu M-Y, Chiu Y-C, Tang C-H, Hour M-J, et al. 5-Lipoxygenase inhibitors attenuate TNF-α-induced inflammation in human synovial fibroblasts. PLoS One [Internet]. 2014;9:e107890–e107890.CrossRef
10.
Manev H, Chen H, Dzitoyeva S, Manev R. Cyclooxygenases and 5-lipoxygenase in Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry [Internet]. 2011;35:315–9.PubMedCrossRef
11.
Martel-Pelletier J, Lajeunesse D, Reboul P, Pelletier J-P. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis [Internet]. 2003;62:501–9.PubMedPubMedCentralCrossRef
12.
13.
Nicholls JM, Poon LLM, Lee KC, Ng WF, Lai ST, Leung CY, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet (London, England) [Internet]. 2003;361:1773–8.
14.
Peiris JSM, Chu CM, Cheng VCC, Chan KS, Hung IFN, Poon LLM, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet (London, England) [Internet]. 2003;361:1767–72.CrossRef
15.
Zhang Y, Li J, Zhan Y, Wu L, Yu X, Zhang W, et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun [Internet]. 2004;72:4410–5.CrossRef
16.
Bradley BT, Bryan A. Emerging respiratory infections: the infectious disease pathology of SARS, MERS, pandemic influenza, and legionella. Semin Diagn Pathol [Internet]. 2019;36:152–9.PubMedPubMedCentralCrossRef
17.
Yeung M-L, Yao Y, Jia L, Chan JFW, Chan K-H, Cheung K-F, et al. MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2. Nat Microbiol [Internet]. 2016;1:16004.PubMedPubMedCentralCrossRef
18.
19.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.PubMedPubMedCentralCrossRef
20.
21.
Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical–therapeutic staging proposal. J Hear Lung Transplant [Internet]. 2020;39:405–7.CrossRef
22.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) Outbreak in China: Summary of a report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–42.CrossRefPubMed
23.
Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J [Internet]. 2020;55:2000607.PubMedCrossRef
24.
25.
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N Engl J Med [Internet]. 2020;382:1787–99.PubMedCrossRef
26.
27.
Ong EZ, Chan YFZ, Leong WY, Lee NMY, Kalimuddin S, Haja Mohideen SM, et al. A dynamic immune response shapes COVID-19 progression. Cell Host Microbe [Internet]. 2020;27:879–82.PubMedPubMedCentralCrossRef
28.
29.
30.
Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ [Internet]. 2020;27:1451–4.PubMedPubMedCentralCrossRef
31.
Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol [Internet]. 2020;6:353–60.CrossRef
32.
Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol [Internet]. 2020;15:700–4.PubMedPubMedCentralCrossRef
33.
34.
Werner C, Scullen T, Mathkour M, Zeoli T, Beighley A, Kilgore MD, et al. Neurological impact of coronavirus disease of 2019: practical considerations for the neuroscience community. World Neurosurg [Internet]. 2020;139:344–54.PubMedPubMedCentralCrossRef
35.
Chu LS, Fang SH, Zhou Y, Yu GL, Wang ML, Zhang WP, et al. Minocycline inhibits 5-lipoxygenase activation and brain inflammation after focal cerebral ischemia in rats. Acta Pharmacol Sin [Internet]. 2007;28:763–72.PubMedCrossRef
36.
Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020;323:1612–4.PubMedPubMedCentralCrossRef
37.
Batlle D, Soler MJ, Sparks MA, Hiremath S, South AM, Welling PA, et al. Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology. J Am Soc Nephrol [Internet]. 2020;31:1380–3.PubMedPubMedCentralCrossRef
38.
Merad M, Martin JC. Author correction: pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol [Internet]. 2020;20:448.PubMedCrossRefPubMedCentral
39.
40.
Babapoor-Farrokhran S, Gill D, Walker J, Rasekhi RT, Bozorgnia B, Amanullah A. Myocardial injury and COVID-19: possible mechanisms. Life Sci [Internet]. 2020;253:5.
41.
Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol [Internet]. 2020;20:363–74.PubMedCrossRef
42.
43.
44.
Ebert R, Cumbana R, Lehmann C, Kutzner L, Toewe A, Ferreirós N, et al. Long-term stimulation of toll-like receptor-2 and -4 upregulates 5-LO and 15-LO-2 expression thereby inducing a lipid mediator shift in human monocyte-derived macrophages. Biochim Biophys Acta. 2020;1865:158702.CrossRef
45.
Poeckel D, Funk CD. The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease. Cardiovasc Res [Internet]. 2010;86:243–53.PubMedCrossRef
46.
Fang W-F, Douglas IS, Wang C-C, Kao H-C, Chang Y-T, Tseng C-C, et al. 5-Lipoxygenase activating protein (FLAP) dependent leukotriene biosynthesis inhibition (MK591) attenuates lipid A endotoxin-induced inflammation. PLoS One [Internet]. 2014;9:e102622.PubMedCrossRef
47.
McCarthy MK, Weinberg JB. Eicosanoids and respiratory viral infection: coordinators of inflammation and potential therapeutic targets. Mediators Inflamm. 2012;2012:236345.PubMedPubMedCentralCrossRef
48.
49.
Yokomizo T. Two distinct leukotriene B4 receptors, BLT1 and BLT2. J Biochem [Internet]. 2015;157:65–71.PubMedCrossRef
50.
51.
Behrens EM, Canna SW, Slade K, Rao S, Kreiger PA, Paessler M, et al. Repeated TLR9 stimulation results in macrophage activation syndrome: like disease in mice. J Clin Invest [Internet]. 2011;121:2264–77.PubMedPubMedCentralCrossRef
52.
Yan B, Chu H, Yang D, Sze K-H, Lai P-M, Yuan S, et al. Characterization of the lipidomic profile of human coronavirus-infected cells: implications for lipid metabolism remodeling upon coronavirus replication. Viruses [Internet]. 2019;11:73.PubMedCentralCrossRef
53.
54.
55.
Wang Z, Filgueiras LR, Wang S, Serezani APM, Peters-Golden M, Jancar S, et al. Leukotriene B 4 enhances the generation of proinflammatory microRNAs to promote MyD88-dependent macrophage activation. J Immunol [Internet]. 2014;192:2349–56.PubMedPubMedCentralCrossRef
56.
Kumar V. Inflammasomes: pandora’s box for sepsis. J Inflamm Res [Internet]. 2015;11:477–502.CrossRef
57.
58.
Van Schaik SM, Tristram DA, Nagpal IS, Hintz KM, Welliver RC, Welliver RC. Increased production of IFN-γ and cysteinyl leukotrienes in virus- induced wheezing. J Allergy Clin Immunol [Internet]. 1999;103:630–6.PubMedCrossRef
59.
Delia RV, Harrison K, Oyston PC, Lukaszewski RA, Clark GC. Targeting the “Cytokine Storm” for therapeutic benefit. Clin Vaccine Immunol. 2013;20:319–27.CrossRef
60.
61.
62.
Weide I, Römisch J, Simmet T. Contact activation triggers stimulation of the monocyte 5-lipoxygenase pathway via plasmin. Blood Am Soc Hematol. 1994;83:1941–51.
63.
Yang Y, Tang H. Aberrant coagulation causes a hyper-inflammatory response in severe influenza pneumonia [Internet]. Cell. Mol. Immunol. Chinese Soc Immunology; 2016 [cited 2020 Aug 11]. p. 432–42. Available from: www.​nature.​com/​cmi
64.
Guo Y, Li J, Hagström E, Ny T. Beneficial and Detrimental Effects of Plasmin(ogen) during Infection and Sepsis in Mice. Chakravortty D, editor. PLoS One [Internet]. Public Library of Science; 2011 [cited 2020 Aug 11];6:e24774. Available from: https://​dx.​plos.​org/​https://​doi.​org/​10.​1371/​journal.​pone.​0024774
65.
66.
67.
68.
Zilow G, Joka T, Obertacke U, Rother U, Kirschfink M. Generation of anaphylatoxin C3a in plasma and bronchoalveolar lavage fluid in trauma patients at risk for the adult respiratory distress syndrome. Crit Care Med [Internet]. 1992;20:468–73.PubMedCrossRef
69.
Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol [Internet]. 2007;171:715–27.PubMedPubMedCentralCrossRef
70.
Buckley CD, Gilroy DW, Serhan CN. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity [Internet]. 2014;40:315–27.PubMedPubMedCentralCrossRef
71.
Italiani P, Boraschi D. From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation. Front Immunol [Internet]. 2014;5:514.PubMedPubMedCentral
72.
73.
Collin M, Rossi A, Cuzzocrea S, Patel NSA, Di Paola R, Hadley J, et al. Reduction of the multiple organ injury and dysfunction caused by endotoxemia in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. J Leukoc Biol [Internet]. 2004;76:961–70.PubMedCrossRef
74.
Venkataraman T, Frieman MB. The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis. Antiviral Res. 2017;143:142–50.PubMedPubMedCentralCrossRef
75.
76.
Montford JR, Bauer C, Dobrinskikh E, Hopp K, Levi M, Weiser-Evans M, et al. Inhibition of 5-lipoxygenase decreases renal fibrosis and progression of chronic kidney disease. Am J Physiol - Ren Physiol [Internet]. 2019;316:F732–42.CrossRef
77.
Zhu X, Wang Y, Zhang H, Liu X, Chen T, Yang R, et al. Genetic variation of the human α-2-Heremans-Schmid Glycoprotein (AHSG) gene associated with the risk of SARS-CoV infection. PLoS One [Internet]. 2011;6:e23730.PubMedCrossRef
78.
Turner MD, Nedjai B, Hurst T, Pennington DJ. Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. Biochim Biophys Acta - Mol Cell Res. 2014;1843:2563–82.CrossRef
79.
80.
Tschaikowsky K, Hedwig-Geissing M, Schiele A, Bremer F, Schywalsky M, Schüttler J. Coincidence of pro- and anti-inflammatory responses in the early phase of severe sepsis: longitudinal study of mononuclear histocompatibility leukocyte antigen-DR expression, procalcitonin, C-reactive protein, and changes in T-cell subsets in septic and postoperative patients. Crit Care Med [Internet]. 2002;30:1015–23.PubMedCrossRef
81.
Tam VC, Quehenberger O, Oshansky CM, Suen R, Armando AM, Treuting PM, et al. Lipidomic profiling of influenza infection identifies mediators that induce and resolve inflammation. Cell. 2013;154:213.PubMedPubMedCentralCrossRef
82.
83.
84.
85.
O’Flaherty JT, Hu Y, Wooten RE, Horita DA, Samuel MP, Thomas MJ, et al. 15-Lipoxygenase metabolites of docosahexaenoic acid inhibit prostate cancer cell proliferation and survival. PLoS ONE. 2012;7:e45480.PubMedPubMedCentralCrossRef
86.
Rådmark O, Werz O, Steinhilber D, Samuelsson B. 5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease. Biochim Biophys Acta. 2015;1851:331–9.PubMedCrossRef
87.
Rask-Madsen J, Bukhave K, Laursen LS, Lauritsen K. 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease. Agents Actions. 1992;36:C37-46.CrossRef
88.
Shirey KA, Lai W, Pletneva LM, Karp CL, Divanovic S, Blanco JCG, et al. Role of the lipoxygenase pathway in RSV-induced alternatively activated macrophages leading to resolution of lung pathology. Mucosal Immunol Nature Publishing Group. 2014;7:549–57.CrossRef
89.
Bruno F, Spaziano G, Liparulo A, Roviezzo F, Nabavi SM, Sureda A, et al. Recent advances in the search for novel 5-lipoxygenase inhibitors for the treatment of asthma. Eur J Med Chem. 2018;153:65–72.PubMedCrossRef
90.
Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, Kagan E, et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol. 2003;163:2371–82.PubMedPubMedCentralCrossRef
91.
Zeldin DC. The 5-lipoxygenase pathway: a new therapeutic target for the treatment of pulmonary fibrosis. Am J Respir Crit Care Med. 2002;165:146–7.PubMedCrossRef
92.
Hu W, Yen YT, Singh S, Kao CL, Wu-Hsieh BA. SARS-CoV regulates immune function-related gene expression in human monocytic cells. Viral Immunol. 2012;25:277–88.PubMedPubMedCentralCrossRef
93.
94.
95.
Islam1 R, Fische A. A transcriptome analysis identifies potential preventive and therapeutic 1 approaches towards COVID-19. 2 3 Rezaul Islam. Preprints [Internet]. MDPI AG; 2020 [cited 2020 Aug 9];1–21. Available from: www.​preprints.​org
96.
97.
98.
Singh VP, Patil C, Kumar M, Kulkarni S. Effect of 5-lipoxygenase inhibitor against lipopolysaccharide-induced hypothermia in mice. Indian J Exp Biol. 2006;43:1150–5.
99.
100.
McMurray RW. Nonstandard and adjunctive medical therapies for systemic lupus erythematosus. Arthritis Care Res (Hoboken) [Internet]. 2001;45:86–100.CrossRef
101.
102.
Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol [Internet]. 1991;102:769–73.PubMedPubMedCentralCrossRef
103.
104.
105.
Ricciardolo FLM, Folkerts G, Folino A, Mognetti B. Bradykinin in asthma: Modulation of airway inflammation and remodelling. Eur J Pharmacol [Internet]. 2018;827:181–8.PubMedCrossRef
106.
Gobeil F, Sirois P, Regoli D. Preclinical pharmacology, metabolic stability, pharmacokinetics and toxicology of the peptidic kinin B1 receptor antagonist R-954. Peptides [Internet]. 2014;52:82–9.PubMedCrossRef
107.
108.
Garscha U, Voelker S, Pace S, Gerstmeier J, Emini B, Liening S, et al. BRP-187: a potent inhibitor of leukotriene biosynthesis that acts through impeding the dynamic 5-lipoxygenase/5-lipoxygenase-activating protein (FLAP) complex assembly. Biochem Pharmacol [Internet]. 2016;119:17–26.PubMedCrossRef
109.
Hu C, Ma S. Recent development of lipoxygenase inhibitors as anti-inflammatory agents. Medchemcomm [Internet]. 2018;9:212–25.PubMedCrossRef
110.
Mashima R, Okuyama T. The role of lipoxygenases in pathophysiology; new insights and future perspectives. Redox Biol [Internet]. 2015;6:297–310.PubMedPubMedCentralCrossRef
111.
Rabaan AA, Al-Ahmed SH, Sah R, Tiwari R, Yatoo MI, Patel SK, et al. SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. Ann Clin Microbiol Antimicrob [Internet]. 2020;19:40.PubMedPubMedCentralCrossRef
112.
113.
114.
115.
Liu PP, Blet A, Smyth D, Li H. The science underlying COVID-19: implications for the cardiovascular system. Circulation [Internet]. 2020;142:68–78.PubMedCrossRef
116.
Norris V, Singh D, Boyce M, Kent S, Bentley J. Inhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2190915: a dose–response study. Int J Gen Med [Internet]. 2013;6:897.PubMedPubMedCentralCrossRef
117.
Joshi YB, Praticò D. The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer’s disease phenotype. Front Cell Neurosci [Internet]. 2015;8:436.PubMedPubMedCentral
Metadaten
Titel
The role of 5-lipoxygenase in the pathophysiology of COVID-19 and its therapeutic implications
verfasst von
Nohora Cristina Ayola-Serrano
Namrata Roy
Zareena Fathah
Mohammed Moustapha Anwar
Bivek Singh
Nour Ammar
Ranjit Sah
Areej Elba
Rawan Sobhi Utt
Samuel Pecho-Silva
Alfonso J. Rodriguez-Morales
Kuldeep Dhama
Sadeq Quraishi
Publikationsdatum
04.06.2021
Verlag
Springer International Publishing
Schlagwort
COVID-19
Erschienen in
Inflammation Research / Ausgabe 8/2021
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-021-01473-y

Weitere Artikel der Ausgabe 8/2021

Inflammation Research 8/2021 Zur Ausgabe

Original Research Paper

Hydrogen alleviates cell damage and acute lung injury in sepsis via PINK1/Parkin-mediated mitophagy

Original Research Paper

MicroRNA 452 regulates IL20RA-mediated JAK1/STAT3 pathway in inflammatory colitis and colorectal cancer

Review

SARS-CoV-2 and pathological matrix remodeling mediators

Original Research Paper

Pseudomonas aeruginosa outer membrane vesicles ameliorates lung ischemia–reperfusion injury by regulating the balance of regulatory T cells and Th17 cells through Tim-3 and TLR4/NF-κB pathway

Review

The pathophysiology of immunoporosis: innovative therapeutic targets

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise